The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Canarypox virus

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Canarypox virus


High impact information on Canarypox virus

  • Immunisation with canarypox virus expressing rabies glycoprotein [6].
  • Several canarypox virus recombinants expressing human or murine p53 in wild-type or mutant form were constructed [7].
  • HLA-A*0201-restricted CTL against human gp100 were isolated from HLA-A*0201/K(b) (A2/K(b))-transgenic mice immunized with recombinant canarypox virus (ALVAC-gp100) [8].
  • The objective of this study was to evaluate the safety and activity of the intratumoral administration of the immune costimulatory molecule, B7.1, encoded by a vector derived from the canarypox virus, ALVAC (ALVAC-B7.1), alone and with the intratumoral injection of ALVAC encoding the immune-stimulatory cytokine, interleukin 12 (ALVAC-IL-12) [9].
  • Virologic and serologic follow-up showed that the controls and the two chimpanzees immunized with the live recombinant canarypox virus became infected, whereas the other animals that were immunized with gp160 and V3-MN peptides were protected from infection [10].

Chemical compound and disease context of Canarypox virus


Anatomical context of Canarypox virus


Gene context of Canarypox virus

  • In contrast, established RM11psa tumors ranging in size from 500 to 1,000 mm(3) were efficiently eliminated if Ad5-PSA priming was followed 7 days later by intratumoral injection of recombinant canarypox viruses (ALVAC) encoding interleukin-12 (IL-12), IL-2, and tumor necrosis factor-alpha [4].
  • The development of canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) is described [5].
  • Immunization of mice with a recombinant canarypox virus, ALVAC, expressing human wild-type p53 (vCP207) prevented growth of p53-over-expressing tumors [14].


  1. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model. Siemens, D.R., Austin, J.C., Hedican, S.P., Tartaglia, J., Ratliff, T.L. J. Natl. Cancer Inst. (2000) [Pubmed]
  2. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response. Ullenhag, G.J., Frödin, J.E., Mosolits, S., Kiaii, S., Hassan, M., Bonnet, M.C., Moingeon, P., Mellstedt, H., Rabbani, H. Clin. Cancer Res. (2003) [Pubmed]
  3. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. Stephensen, C.B., Welter, J., Thaker, S.R., Taylor, J., Tartaglia, J., Paoletti, E. J. Virol. (1997) [Pubmed]
  4. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Elzey, B.D., Siemens, D.R., Ratliff, T.L., Lubaroff, D.M. Int. J. Cancer (2001) [Pubmed]
  5. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Taylor, J., Weinberg, R., Tartaglia, J., Richardson, C., Alkhatib, G., Briedis, D., Appel, M., Norton, E., Paoletti, E. Virology (1992) [Pubmed]
  6. Immunisation with canarypox virus expressing rabies glycoprotein. Cadoz, M., Strady, A., Meignier, B., Taylor, J., Tartaglia, J., Paoletti, E., Plotkin, S. Lancet (1992) [Pubmed]
  7. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., Levine, A.J. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  8. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. Sutmuller, R.P., Schurmans, L.R., van Duivenvoorde, L.M., Tine, J.A., van Der Voort, E.I., Toes, R.E., Melief, C.J., Jager, M.J., Offringa, R. J. Immunol. (2000) [Pubmed]
  9. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Triozzi, P.L., Allen, K.O., Carlisle, R.R., Craig, M., LoBuglio, A.F., Conry, R.M. Clin. Cancer Res. (2005) [Pubmed]
  10. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. Girard, M., Meignier, B., Barré-Sinoussi, F., Kieny, M.P., Matthews, T., Muchmore, E., Nara, P.L., Wei, Q., Rimsky, L., Weinhold, K. J. Virol. (1995) [Pubmed]
  11. Identification of the canarypox virus thymidine kinase gene and insertion of foreign genes. Amano, H., Morikawa, S., Shimizu, H., Shoji, I., Kurosawa, D., Matsuura, Y., Miyamura, T., Ueda, Y. Virology (1999) [Pubmed]
  12. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. Coëffier, E., Excler, J.L., Kieny, M.P., Meignier, B., Moste, C., Tartaglia, J., Pialoux, G., Salmon-Céron, D., Leclerc, C. AIDS Res. Hum. Retroviruses (1997) [Pubmed]
  13. Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice. Lenfant, F., Pizzato, N., Liang, S., Davrinche, C., Le Bouteiller, P., Horuzsko, A. J. Gen. Virol. (2003) [Pubmed]
  14. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Rosenwirth, B., Kuhn, E.M., Heeney, J.L., Hurpin, C., Tartaglia, J., Bonnet, M.C., Moingeon, P., Erdile, L. Vaccine (2001) [Pubmed]
WikiGenes - Universities